RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063. The data were presented today at the 8th World Congress on Trauma, Shock, Inflammation and Sepsis (TSIS) in Munich, Germany. TSIS is a medical conference which focuses on the latest knowledge, developments and innovative concepts related to the recognition of disease as well as patient care and therapy within the wide field of acute and chronic systemic inflammation.
